DE3751214T2 - Monoclonal antibodies against immunoglobulin G Fc receptors on human mononuclear phagocytes; bifunctional antibodies; target-specific effector cells; targeted macrophages and immunoassays. - Google Patents

Monoclonal antibodies against immunoglobulin G Fc receptors on human mononuclear phagocytes; bifunctional antibodies; target-specific effector cells; targeted macrophages and immunoassays.

Info

Publication number
DE3751214T2
DE3751214T2 DE3751214T DE3751214T DE3751214T2 DE 3751214 T2 DE3751214 T2 DE 3751214T2 DE 3751214 T DE3751214 T DE 3751214T DE 3751214 T DE3751214 T DE 3751214T DE 3751214 T2 DE3751214 T2 DE 3751214T2
Authority
DE
Germany
Prior art keywords
receptor
antibody
target
immunoassays
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3751214T
Other languages
German (de)
Other versions
DE3751214D1 (en
Inventor
Michael W Fanger
Paul M Guyre
Clark L Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of DE3751214D1 publication Critical patent/DE3751214D1/en
Application granted granted Critical
Publication of DE3751214T2 publication Critical patent/DE3751214T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

A human Fc receptor-specific monoclonal antibody is disclosed together with its mode of preparation. Binding of the antibody to Fc receptor is not blocked by human immunoglobulin G. The antibody binds to the high affinity Fc receptor for IgG on human monocytes at a receptor binding site distinct from the ligand binding site for Fc. A bifunctional antibody or a heteroantibody has an antigen binding region derived from an anti-Fc receptor antibody and an antigen binding region specific for a target epitope or cell; such antibody may target a macrophage when it is bound to surface Fc receptors of the macrophage. A target-specific effector cell expresses receptor for the Fg portion of IgG, has one antigen binding region derived from an anti-Fc receptor antibody and another specific for a target cell, and the aforesaid bifunctional or hetero-antibody is bound to the Fc receptor of the effector cell; such effector cell can be used in the therapy of cancers, allergies, infectious and autoimmune diseases, and in immunoassays.
DE3751214T 1986-07-07 1987-07-07 Monoclonal antibodies against immunoglobulin G Fc receptors on human mononuclear phagocytes; bifunctional antibodies; target-specific effector cells; targeted macrophages and immunoassays. Expired - Lifetime DE3751214T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88218186A 1986-07-07 1986-07-07
US07/069,412 US4954617A (en) 1986-07-07 1987-07-01 Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes

Publications (2)

Publication Number Publication Date
DE3751214D1 DE3751214D1 (en) 1995-05-11
DE3751214T2 true DE3751214T2 (en) 1995-11-16

Family

ID=26750030

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751214T Expired - Lifetime DE3751214T2 (en) 1986-07-07 1987-07-07 Monoclonal antibodies against immunoglobulin G Fc receptors on human mononuclear phagocytes; bifunctional antibodies; target-specific effector cells; targeted macrophages and immunoassays.

Country Status (10)

Country Link
US (1) US4954617A (en)
EP (2) EP0255249B1 (en)
AT (1) ATE120802T1 (en)
AU (1) AU605771B2 (en)
CA (1) CA1319899C (en)
DE (1) DE3751214T2 (en)
ES (1) ES2072851T3 (en)
IL (2) IL83113A0 (en)
NZ (1) NZ220973A (en)
WO (1) WO1988000052A1 (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
US5635600A (en) * 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
JP2755395B2 (en) * 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Antibody heteroconjugate that kills HIV-infected cells
WO1989006544A1 (en) * 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
EP0739904A1 (en) * 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
FR2653561A1 (en) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San ANTI-RHD HETERO-ANTIBODIES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
EP0595798B1 (en) 1989-10-20 1999-03-03 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
EP0496818B1 (en) * 1989-10-20 1999-06-23 Trustees Of Dartmouth College MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
JP3583420B2 (en) * 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド Targeted immunization with bispecific reagents
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE153768T1 (en) * 1991-01-15 1997-06-15 Bayer Ag SUPPLEMENT OF SURFACE RECEPTORS
US5994514A (en) * 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
DE69233716T2 (en) * 1991-08-14 2008-10-30 Genentech Inc., San Francisco Immunoglobulin variants for specific Fc epsilon receptors
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
WO1994008038A1 (en) * 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5487975A (en) * 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
JPH09510201A (en) * 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド Bispecific molecules with clinical utility
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
FI951778A (en) * 1995-04-12 1996-10-13 Aboatech Ab Oy Method for diagnosing allergies
US20030144483A1 (en) * 1995-05-04 2003-07-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
DE69609510T2 (en) * 1995-06-07 2001-04-19 Medarex Inc BISPECIFIC MOLECULES AGAINST ALLERGY
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ES2176574T3 (en) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY.
AU721792B2 (en) * 1996-09-06 2000-07-13 Medarex, Inc. Cyanidin compositions and therapeutic and diagnostic uses therefor
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2311574A1 (en) 1997-12-02 1999-06-10 Medarex, Inc. Cells expressing anti-fc receptor binding components
US20020058284A1 (en) * 1998-02-17 2002-05-16 Jan G.J. Van De Winkel Methods and compositions for treating macrophage-mediated diseases
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
KR100942863B1 (en) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 Human ctla-4 antibodies and their uses
US20010051147A1 (en) * 2000-03-27 2001-12-13 Van De Winkel Jan G.J. Methods for immunostimulation using binding agents for the Fc receptor of immunoglobulin A
JP5007409B2 (en) * 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション Human monoclonal antibodies against dendritic cells
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2003030835A2 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
KR100944575B1 (en) 2002-10-17 2010-02-25 젠맵 에이/에스 Human monoclonal antibodies against cd20
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1594533B1 (en) * 2003-01-31 2012-04-11 Celldex Research Corporation Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
DK1711207T3 (en) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha antibodies and their use
CN102838675B (en) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10 antibodies and their uses
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
WO2005071058A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
ES2526194T3 (en) 2004-06-21 2015-01-08 E. R. Squibb & Sons, L.L.C. Interferon alfa 1 receptor antibodies, and their uses
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
RS59399B1 (en) 2005-03-23 2019-11-29 Genmab As Antibodies against cd38 for treatment of multiple myeloma
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
RU2421464C2 (en) 2005-10-21 2011-06-20 Новартис Аг Human il-13 antibodies and their therapeutic application
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2638902C (en) 2005-12-08 2014-09-23 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CN101627055A (en) 2006-09-05 2010-01-13 梅达雷克斯公司 The antibody of bone morphogenetic protein and acceptor thereof and their using method
LT2081595T (en) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
SI2066351T1 (en) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Human antibodies that bind cxcr4 and uses thereof
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
EA200970477A1 (en) 2006-11-15 2009-12-30 Медарекс, Инк. HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION
KR20150067395A (en) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. Human antibodies that bind cd22 and uses thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
PT2769729T (en) 2007-09-04 2019-05-08 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
KR101811965B1 (en) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human dendritic and epithelial cell 205(dec-205)
CA2713055C (en) * 2008-01-25 2018-03-13 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2650017A3 (en) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
EP3045475B1 (en) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
US8802093B2 (en) 2008-04-02 2014-08-12 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
CN105641694B (en) 2008-12-19 2020-08-14 H.隆德贝克有限公司 Modulation of the Vps10 p-domain receptor family for the treatment of mental and behavioural disorders
PT2403878T (en) 2009-03-05 2017-09-01 Squibb & Sons Llc Fully human antibodies specific to cadm1
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
PE20130479A1 (en) 2010-03-04 2013-05-12 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMULOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2697256A1 (en) 2011-04-15 2014-02-19 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2840537C (en) 2011-06-28 2021-12-14 Oxford Biotherapeutics Ltd. Antibodies to adp-ribosyl cyclase 2
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
MX2014009289A (en) 2012-02-01 2015-09-08 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer.
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (en) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ VISTA modulators for cancer diagnosis and treatment
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP3055331B1 (en) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
SI3712174T1 (en) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
RU2638457C2 (en) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production
ITUB20155272A1 (en) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
JP2019509993A (en) 2016-02-12 2019-04-11 ヤンセン ファーマシューティカ エヌブイ Anti-VISTA (B7H5) antibody
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
IL262396B2 (en) 2016-04-15 2023-09-01 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP4092045A1 (en) 2016-05-16 2022-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
EP3584258A1 (en) 2018-06-19 2019-12-25 IEO - Istituto Europeo di Oncologia Srl Antibodies anti tumor associated antigens and method for obtaining them
US20220229062A1 (en) * 2021-01-21 2022-07-21 Diagnostic Biosystems Method for rapid immunohistochemical detection of an antigen from a biological sample

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2322533C2 (en) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Method for binding immunoglobulin and tools for carrying out the method
IL57108A (en) * 1979-04-22 1981-12-31 Yeda Res & Dev Assay for the quantitative determination of interferon and a kit therefor
WO1982001773A1 (en) * 1980-11-07 1982-05-27 Secher David S Assay for interferon
US4481298A (en) * 1981-04-13 1984-11-06 Amf Incorporated Pre-precipitated double antibody immunoassay method
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4479895A (en) * 1982-05-05 1984-10-30 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
CA1194415A (en) * 1982-05-05 1985-10-01 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
EP0094463A3 (en) * 1982-05-17 1985-08-21 Beta Instrument Company Limited Optical measuring apparatus
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
DE3404302C1 (en) * 1984-02-08 1985-06-05 Hermann Hemscheidt Maschinenfabrik Gmbh & Co, 5600 Wuppertal Control device for a hydraulic stepping frame
JPH0736016B2 (en) * 1984-05-11 1995-04-19 和光純薬工業株式会社 Immunoglobulin quantification method
JPS6147500A (en) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0259585B1 (en) * 1986-07-29 1993-06-09 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for ige and hybrid cell lines producing these antibodies and use thereof

Also Published As

Publication number Publication date
DE3751214D1 (en) 1995-05-11
US4954617A (en) 1990-09-04
ES2072851T3 (en) 1995-08-01
EP0629703A2 (en) 1994-12-21
NZ220973A (en) 1989-11-28
AU605771B2 (en) 1991-01-24
IL83113A0 (en) 1987-12-31
AU7527187A (en) 1988-01-14
EP0629703A3 (en) 1995-03-22
IL83113A (en) 1992-11-15
EP0255249B1 (en) 1995-04-05
EP0255249A3 (en) 1990-03-07
EP0255249A2 (en) 1988-02-03
ATE120802T1 (en) 1995-04-15
WO1988000052A1 (en) 1988-01-14
CA1319899C (en) 1993-07-06

Similar Documents

Publication Publication Date Title
DE3751214D1 (en) Monoclonal antibodies against immunoglobulin G Fc receptors on human mononuclear phagocytes; bifunctional antibodies; target-specific effector cells; targeted macrophages and immunoassays.
DK0595798T3 (en) Bispecific hetero antibodies with dual effector functions
DE69221147D1 (en) Anti-glycosylated anti-CD3 IgG antibody
ATE197316T1 (en) MONOCLONAL ANTIBODIES AGAINST DEFINED REGIONS OF THE T-CELL ANTIGEN RECEPTOR
ATE170562T1 (en) CTL4A RECEPTOR, FUSION PROTEINS CONTAINING IT AND USES THEREOF
NL300220I2 (en) Immunoglobulin variants for specific FC epsilon receptors.
EP0867189A3 (en) Monoclonal antibodies reactive with defined regions of the T cell antigen receptor
AU6054398A (en) Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
WO2003106495A3 (en) Humanized monoclonal antiboby hpam4
CA2118010A1 (en) Antibodies specific for carcinoma-associated antigens
DE3788296D1 (en) Monoclonal antibodies to human interleukin-2 receptor.
Steinitz et al. In vitro produced monoclonal rheumatoid factor: purification, radiolabel, and possible applications
Jansson et al. A biotin-labelled antigen radioimmunoassay (BILA) for antibodies to membrane antigens useful for monoclonal antibody screening
Svenson et al. Measurement of cytokine antibodies. Test development
Cavenaugh et al. How well can an idiotope peptide mimic replace its parent idiotype in a synthetic peptide vaccine?
Endresen Studies on the steric relationship between HLA antigens, beta2-microglobulin and the Fc receptor on human platelets
Yelton STRUCTURE AND FUNCTION OF MUTANT MONOCLONAL ANTIBODIES PRODUCED BY HYBRID CELL LINES.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MEDAREX, INC., ANNANDALE, N.J., US

8364 No opposition during term of opposition